

CASE REPORT

Management of intrathoracic phosphaturic mesenchymal tumor by nonintubated uniportal video-assisted thoracic surgery in a fragile patient

Michele Ferrari^{1,2}  | Alessandro Palleschi^{1,2} | Francesca Bartoli³ |
Federico Polli⁴ | Elisabetta Armiraglio⁵ | Antonina Parafioriti⁵ |
Giorgio A. Croci^{1,6} | Davide Tosi^{1,2}

¹Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

²Thoracic Surgery and Lung Transplantation Unit, Fondazione IRCCS Ca' Granda—Ospedale Maggiore Policlinico, Milan, Italy

³Department of Rheumatology, Gaetano Pini Institute, Milan, Italy

⁴Department of Anaesthesia, Critical Care and Emergency Medicine, Fondazione IRCCS Ca' Granda—Ospedale Maggiore Policlinico, Milan, Italy

⁵Department of Pathology, ASST-PINI-CTO Centro Specialistico Ortopedico Traumatologico Gaetano Pini, Milan, Italy

⁶Division of Pathology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy

Correspondence

Michele Ferrari, MD, Division of Thoracic Surgery and Lung transplant Unit, Fondazione IRCCS Ca' Granda—Ospedale Maggiore Policlinico Via Francesco Sforza 28, Milan 20123, Italy.
Email: michele.ferrari1990@gmail.com

Abstract

Background: Phosphaturic mesenchymal tumors are rare neoplasms, frequently presenting with osteomalacia. These neoplasms usually grow at a slow rate and are associated with unspecific symptoms.

Case: In this study, we present the case of a 70-year-old woman who had been suffering from musculoskeletal pain, hypophosphatemia, and spontaneous fractures. Positron emission tomography with Gallium showed increase uptake in a subpleural lesion.

Conclusion: The patient underwent surgical excision of the subpleural lesion with a non-intubated uniportal video-assisted thoracoscopic surgery approach.

KEYWORDS

hypophosphatemia, NITS, phosphaturic mesenchymal tumors, uniportal VATS

1 | INTRODUCTION

Phosphaturic mesenchymal tumors (PMTs) are rare mesenchymal tumors that produce a phosphate substance, fibroblast growth factor-23 (FGF23), causing systemic phosphate depletion and leading to oncogenic osteomalacia. Osteomalacia is linked to an increased circulating level of FGF-23, produced by the PMT, which reduces renal reabsorption of phosphate and inhibits 25-hydroxyvitamin D1- α -hydroxylase function.^{1,2} Significant factors contributing to late

diagnosis are the slow growth and small size of the mass, as well as non-specific clinical characteristics (bone pain, spontaneous fractures, muscle weakness, and impaired gait). Patients are extremely fragile because of the substantial number of bone fractures they sustain.³ Usually, surgical excision of the tumor is the treatment of choice for PMT, but surgery is sometimes contraindicated due to several coexisting comorbidities.⁴

Historically, thoracic surgery has always been performed under general anesthesia using a double-lumen endotracheal tube, which allows one-lung ventilation. In recent years, new anaesthesiologic

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Cancer Reports* published by Wiley Periodicals LLC.



techniques have been developed with a specific interest in non-intubated (spontaneously ventilated) procedures. Nonintubated thoracic surgery (NITS) is performed under loco-regional anesthesia, specifically intercostal/interpleural/paravertebral blocks or epidural anesthesia. The development of minimally invasive techniques like multiportal and uniportal video-assisted thoracic surgery (VATS) has encouraged improvements in postoperative pain management, reduction of postoperative complications and hospital stay. The combination of the uniportal approach and nonintubated anesthesia results in a minimal impact on the patient.^{5,6} We present the clinical case of a symptomatic intrathoracic PMT, treated with non-intubated uniportal VATS.

2 | CASE REPORT

A 70-year-old female patient had been suffering from bone pain, asthenia, and multiple fragility fractures of the lower limbs, pelvis, ribs, and spine for several years. The patient was in poor clinical conditions due to prolonged bed rest because of repeated bone fractures. Although numerous neurological and rheumatological evaluations had been previously performed, all clinical and serum tests gave nonspecific findings, and a definitive diagnosis was not obtained. During her last hospitalization at the Rheumatology Department of the Gaetano Pini Hospital (Milan, Italy), the following laboratory abnormalities were found: low serum phosphorus (Table 1), an improperly normal calcitriol (1,25(OH)2D) and an increased urinary phosphate excretion detected by a reduced tubular maximum phosphate reabsorption per glomerular filtration rate (TMP/GFR).^{7,8} Once these biochemical changes were highlighted, TIO was suspected. A subsequent 68-Gallium DOTATATE positron emission tomography (⁶⁸Ga-DOTATATE PET/CT) confirmed a pathological uptake in a subpleural lesion near the eighth right rib (Figure 1(A), (B)). The patient was then transferred to our department for proper management. The clinical case was presented at the multidisciplinary tumor board meeting and a surgical resection indicated. Due to bone fragility, the passive mobilization of the patient was deemed too risky; to allow active positioning on the operative table, a nonintubated surgical resection of the tumor was planned. In the operative room, after patient's self-positioning in the lateral decubitus position, general anesthesia was induced with propofol (using a target-controlled infusion) and fentanyl; the airway was secured with a laryngeal mask (Ambu® AuraGain™), and spontaneous breathing of 100% oxygen was maintained throughout the procedure. We performed a uniportal VATS resection with the surgeon and the assistant facing the patient. After local anesthesia of the skin (5 ml of lidocaine 2%), a 4-cm utility muscle-sparing incision was performed on the 5th intercostal space and a wound protector (Alexis®, Applied Medical, USA) was positioned; the thoracoscope was always positioned at the upper end of the incision port. After gaining access to the thoracic cavity, four intercostal nerves were blocked with local anesthetic (each with 3 ml of ropivacaine 7.5 mg/ml) under direct thoroscopic vision and the vagus nerve was also blocked near Baret's space (5 ml of ropivacaine 7.5 mg/ml) to reduce the cough reflex. The radical resection of the lesion was carried out without intraoperative complications (Video S1). The postoperative course was uneventful.

TABLE 1 Preoperative values of electrolytes and hormones

Serum phosphorus	0.8 mg/dl
24 h urinary Pi	191 mg
TMP/GFR	0.2 mg/dl
Serum calcium	7.7 mg/dl
24 h urinary Ca	32 mg/24 h
Serum ALP	215 U/L
Intact PTH	153 pg/ml
1,25(OH)2D	45 ng/L
Albumin	3,4 g/dl
Albumin-corrected serum calcium	8,2 mg/dl

Note: Reference values. Serum phosphorus: 2.5–4.6 mg/dl; 24 h urinary Pi: 400–1000 mg; TMP/GFR: 2.3–4.3 mg/dl; Serum calcium: 8.4–10.2 mg/dl; 24 h urinary Ca: 100–300 mg/24 h; Serum ALP: 30–130 U/L; Intact PTH: 15–65 pg/ml; 1,25 (OH)2D: 25–86 ng/L.




FIGURE 1 (A, B) CT images of intrathoracic phosphaturic mesenchymal tumor and rib fracture

Rapid mobilization soon followed. The size of the surgical sample was 30 × 15 × 10 mm. Histologic examination revealed a patternless proliferation of ovoid to spindle cells, featuring minimal atypia and unremarkable mitotic rate, in the absence of necrosis. Immunohistochemical analysis, as routinely performed via automated staining on a Dako OMNIS (Agilent, Carpinteria, CA) platform, disclosed a “vimentin-only” phenotype, without expression of substantial negativity for markers of vascular/endothelial (ERG, CD31, CD34, and podoplanin),




FIGURE 2 (A–D) Histologic Panel of phosphaturic mesenchymal tumor. At scanning magnification (2A. HE), the lesion appears as a mass forming proliferation with a grossly pushing border toward the adipose tissue of the chest wall. At higher magnification (2B. HE, 10 \times) the lesion consists of bland looking ovoid to spindle cells, with an unremarkable mitotic rate and absence of necrosis, growing in a diffuse fashion with irregularly intermixed hematic vascular structures. The detail (2C. HE, 40 \times) underlines the presence of the accumulation of hemosiderin laden macrophages (arrow) and of small foci of myxoid degeneration with finely granular calcifications (arrowhead). Immunohistochemical stain with anti-FGF23 antibody (2D. 40 \times) resulted negative, as compared to the positive control (inset)

muscular (smooth muscle actin, desmin) and neural (S100) differentiation, and low and high molecular weight cytokeratins (Figure 2A–C). In addition, immunohistochemical analysis of FGF23 was performed using a commercially available anti-FGF23 antibody (1:80 dilution; antibodies-online, Aachen, DE), which turned negative (Figure 2D). In the absence of sufficient criteria for the alternative diagnosis of hemangiopericytoma or solitary fibrous tumor, the benign histologic picture together with the clinical history and the laboratory findings prompted a diagnosis of PMT.⁹ The normalization of phosphate levels occurred on 14th postoperative day. During the 1-year follow-up, the patient showed normalization of the electrolyte concentrations, exhibiting no symptoms nor any sign of endothoracic lesions or recurrences noted on repeated CT scans. Due to the remission of the clinical disease, radiological follow-up was stopped and only 6-monthly biochemical monitoring was provided.

3 | DISCUSSION

PMT is tumor of the soft tissue and bone that, in some cases, appears as a paraneoplastic pathologic TIO. This condition was first described by

McCance in 1947.¹⁰ PMTs are classified into four subtypes: phosphoric mesenchymal connective tissue variant (PMTMCT), osteoblastoma-like variant, ossified fibroids-like variant and nonossifying fibroma-like variant. The PMTMCT variant is the most common, making up 70–80% of reported cases.

According to the literature, 46% of the cases of TIO occurred in females and 54% in males, with an average age of 45.3 years at the time of diagnosis.¹¹

In the majority of patients (57%), the tumor arises in bones, while in the remaining 34% cases it originates in soft tissues.¹²

Tumors are usually located in the femur (22.7%), skull (20.7%), ankle and foot (8.8%), pelvis (8.2%), tibia or fibula (6.5%), and arm (6.5%). The intrathoracic localization is uncommon.⁴

In order to locate the culprit tumour, the whole body functional imaging tests should be conducted first. 18-fluoro-deoxy-glucose (F-18 FDG) Positron Emission Tomography/Computed Tomography (F-18 FDG PET/CT) is a very sensitive but not very accurate diagnostic tool.¹³

The best accurate imaging currently available involve the use of radiolabelled tracers for somatostatin receptors (SSTRs) commonly



expressed by PMTs¹⁴; 68Ga-DOTATATE PET/CT, for the highest sensitivity and specificity, is considered the gold standard for tumor localization.¹⁵ Magnetic resonance imaging can effectively confirm the tumor site and the margins with surrounding tissues.¹⁶ Surgical excision with adequate margins is the treatment of choice for these patients because distant metastases are very rare.^{4,10} Within a few days after surgical resection, the serum markers usually return to baseline, while few months are necessary for the complete resolution of the symptoms.² Radiotherapy is a valid alternative when resection is incomplete or for patients who are considered not fit for surgery.¹⁷ Caudell et al. observed that combined therapy (surgery and adjuvant radiotherapy) had better control on disease than radiotherapy alone.¹⁸ Patients with PMT are very fragile and extremely compromised because of long periods of bed resting for recurrent pathological bone fractures and pain. The surgical risk is high and the operation may be contraindicated and comorbidities can play a relevant role in case of intrathoracic growth, however treatment should be mandated as removal of the lesion commonly leads to normalization of laboratory anomalies and, along the follow up, to normalization of the clinical condition. In the case of PMT, manifestations are postulated to be dependent on the production of FGF23. Lack of FGF23 detection via immunohistochemistry did not rule out a diagnosis of PMT in our cases: such a feature is well described^{3,17} and it may depend on the levels of FGF23 secretion by the tumour cells, which may fall below the sensitivity of the commercially available antibodies. For these reasons, NITS was our first choice. Historically, the development of thoracic surgery followed the introduction of mechanical ventilation in the 1960s. Since the early 2000s, interest in NITS procedures has grown in the surgical community; this approach was initially applied to simple procedures only (pleural biopsy or resection of pulmonary bullae). In 2004, Pompeo et al. reported a case series of awake thoracoscopic resections of solitary pulmonary nodules under epidural anesthesia, demonstrating the feasibility and safety of this technique.¹⁹ In 2007, Al-Abdullatif et al. reported the first nonintubated VATS lobectomy in an awake patient.²⁰

Since then, many authors have reported the combination of NITS with thoracoscopic techniques. Rocco et al. have described the technique of resection of pulmonary nodules in awake patients, even in an ambulatory setting.²¹ The combination of NITS and the evolution of VATS, specifically of the uniportal approach, have minimized the invasiveness of the procedures and reduced the hospital stay.²² Common side effects of tracheal intubation and general anesthesia (intubation-related airway trauma, ventilator-induced lung injury, and residual neuromuscular blockage) are less frequent as well, allowing early recovery after the operation. It is relevant to point out that avoiding general anesthesia and one-lung mechanical ventilation could result in a better physiological inflammatory response, leading to oncological advantages in neoplastic patients.²³

Despite all these advantages, NITS has some contraindications such as obesity, neurological conditions, uncontrolled gastroesophageal reflux, central hypoventilation syndrome, persistent cough or mucus retention, hemodynamic instability, and severe hypoxia/

hypercapnia.⁵ Therefore, a careful selection of patients is mandatory to obtain satisfactory results.

This case report describes a classic case of osteomalacia induced PMT. By using the NITS technique, it was possible to have the patient autonomously positioned on the operating table, reducing the risk of further bone fractures during lateral decubitus mobilization. A minimally invasive uniportal approach was used to reduce peri- and post-operative pain and the risk of iatrogenic rib fractures.

The key point of this case report is to highlight the effectiveness of combining the NITS technique with the VATS uniportal approach, which has proven to be an optimal strategy, minimizing peri-operative complications and hospital time.

ACKNOWLEDGMENT

None.

CONFLICT OF INTEREST

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

AUTHOR CONTRIBUTIONS

Michele Ferrari: Conceptualization; formal analysis; methodology; resources; writing-original draft; writing-review & editing. **Alessandro Paleschi:** Conceptualization; formal analysis; methodology; resources; supervision; writing-original draft; writing-review & editing. **Francesca Bartoli:** Conceptualization; formal analysis; methodology; resources; supervision; writing-original draft. **Federico Polli:** Conceptualization; data curation; methodology; writing-original draft. **Elisabetta Armiraglio:** Conceptualization; formal analysis; investigation; resources; writing-original draft; writing-review & editing. **Antonina Parafioriti:** Conceptualization; formal analysis; investigation; methodology; resources; writing-original draft; writing-review & editing. **Giorgio Alberto Croci:** Conceptualization; formal analysis; methodology; resources; writing-original draft; writing-review & editing. **Davide Tosi:** Conceptualization; formal analysis; methodology; project administration; supervision; writing-original draft; writing-review & editing.

ETHICAL STATEMENT

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Written informed patient consent was obtained to publish this report.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Michele Ferrari  <https://orcid.org/0000-0002-2661-9317>

REFERENCES

1. Erben RG. Physiological actions of fibroblast growth factor-23. *Front Endocrinol.* 2018;9:267.

2. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. *Endocr Relat Cancer*. 2011;18(3):R53-R77.
3. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. *Am J Surg Pathol*. 2004;28:1-30.
4. Zuo Q, Wang H, Li W, et al. Treatment and outcomes of tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours: retrospective review of 12 patients. *BMC Musculoskelet Disord*. 2017;18:403.
5. Rocco G. Non-intubated uniportal lung surgery. *Eur J Cardiothorac Surg*. 2016;49(Suppl 1):i3-i5.
6. Mineo TC, Sellitri F, Fabbi E, Ambrogi V. Uniportal non-intubated lung metastasectomy. *J Vis Surg*. 2017;3:118.
7. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. *Lancet*. 1975;2(7929):309-310. [https://doi.org/10.1016/s0140-6736\(75\)92736-1](https://doi.org/10.1016/s0140-6736(75)92736-1)
8. Manghat P, Sodi R, Swaminathan R. Phosphate homeostasis and disorders. *Ann Clin Biochem*. 2014;51(Pt 6):631-656. <https://doi.org/10.1177/0004563214521399>
9. Folpe AL. Phosphaturic mesenchymal tumors: a review and update. *Semin Diagn Pathol*. 2019;36(4):260-268.
10. Mc CR. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. *Q J Med*. 1947;16:33-46.
11. Sundaram M, McCarthy EF. Oncogenic osteomalacia. *Skeletal Radiol*. 2000;29:117-124.
12. Ungari C, Rocchi G, Tinna C, et al. Hypophosphaturic mesenchymal tumour of the ethmoid associated with oncogenic osteomalacia. *J Craniofac Surg*. 2004;15:523-527.
13. Malhotra G, Agrawal A, Jambhekar NA, et al. Interesting image. The search for primary tumor in a patient with oncogenic osteomalacia: F-18 FDG PET resolves the conundrum. *Clin Nucl Med*. 2010;35:896-898.
14. Houang M, Clarkson A, Sioson L, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). *Hum Pathol*. 2013;44(12):2711-2718. <https://doi.org/10.1016/j.humpath.2013.07.016>
15. El-Maouche D, Sadowski SM, Papadakis GZ, et al. (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. *J Clin Endocrinol Metab*. 2016;101(10):3575-3581. <https://doi.org/10.1210/jc.2016-2052>
16. Hautmann AH, Hautmann MG, Kolbl O, et al. Tumor-induced osteomalacia: an up-to-date review. *Curr Rheumatol Rep*. 2015;17:512.
17. Shiba E, Matsuyama A, Shibuya R, et al. Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant. *Diagn Pathol*. 2016;11:26.
18. Caudell JJ, Ballo MT, Zagars GK, et al. Radiotherapy in the management of giant cell tumor of bone. *Int J Radiat Oncol Biol Phys*. 2003;57:158-165.
19. Pompeo E, Mineo D, Rogliani P, Sabato AF, Mineo TC. Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules. *Ann Thorac Surg*. 2004;78:1761-1768.
20. Al-Abdullatief M, Wahood A, Al-Shirawi N, et al. Awake anaesthesia for major thoracic surgical procedures: an observational study. *Eur J Cardiothorac Surg*. 2007;32:346-350.
21. Rocco G, Romano V, Accardo R, et al. Awake single-access (uniportal) video-assisted thoracoscopic surgery for peripheral pulmonary nodules in a complete ambulatory setting. *Ann Thorac Surg*. 2010;89:1625-1627.
22. Hung MH, Chan KC, Liu YJ, et al. Nonintubated thoracoscopic lobectomy for lung cancer using epidural anesthesia and intercostal blockade: a retrospective cohort study of 238 cases. *Medicine*. 2015;94:e727.
23. Furák J, Paróczai D, Burián K, Szabó Z, Zombori T. Oncological advantage of nonintubated thoracic surgery: better compliance of adjuvant treatment after lung lobectomy. *Thorac Cancer*. 2020 Nov;11(11):3309-3316.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Ferrari M, Palleschi A, Bartoli F, et al. Management of intrathoracic phosphaturic mesenchymal tumor by nonintubated uniportal video-assisted thoracic surgery in a fragile patient. *Cancer Reports*. 2021;e1500. <https://doi.org/10.1002/cnr2.1500>